Cancer-causing drug safe and effective in treating eye disease

February 05, 2002

Ophthalmologists at the University of Illinois Medical Center at Chicago have found a highly effective treatment for uveitis, a potentially blinding inflammation of the uvea, the pigmented layers of the eye.

In patients with intractable, sight-threatening, non-infectious uveitis, the drug chlorambucil, a chemotherapeutic agent known to cause cancer in some patients when dispensed long-term, was found effective in alleviating inflammation when administered in high doses for a short time.

The design of the study was a chart review of 53 patients who had been treated at the medical center with high-dose, short-term chlorambucil between 1973 and 1999. With an average follow-up period of four years, 77 percent of the treated patients experienced no recurrence of uveitis, and all patients remained cancer-free. The results appear in the February issue of Ophthalmology, the clinical journal of the American Academy of Ophthalmology.

"The exciting thing about chlorambucil is that it seems to reduce the inflammation in many patients for the long term," said lead author Dr. Debra Goldstein, assistant professor of ophthalmology at the UIC College of Medicine and associate director of the medical center's uveitis service. "Many patients treated with other drugs, such as prednisone and cyclosporine, relapse as soon as the treatment is stopped."

However, Goldstein cautioned, because of the carcinogenic nature of chlorambucil, patients need to be closely monitored.

"Only physicians specializing in or very familiar with the treatment of uveitis and the use of immunosuppressive agents should utilize this treatment," she said. "The treating ophthalmologist may want to work in concert with another physician comfortable with the use of agents such as chlorambucil."

Uveitis is a condition that can be enigmatic and attributable to any number of causes, both infectious and non-infectious. Chlorambucil is used only in non-infectious cases, which are more common.

In less severe cases, uveitis can be controlled by traditional therapies. However, when it is sight-threatening, uveitis is difficult to treat, and many patients find it hard to cope with the side effects of long-term steroid therapy.

Although chlorambucil may become the preferred treatment for patients with severe, non-infectious uveitis, the authors don't recommend the drug for long-term use. What is gratifying, Goldstein said, is that most of the patients treated with chlorambucil went into remission after a short course of therapy.

About 2.3 million people in the United States suffer from ocular inflammatory disorders such as uveitis, according to statistics on blindness and blinding diseases compiled by the University of Washington. Uveitis is estimated to cause 10 percent to 15 percent of blindness in this country.
-end-
Other authors on the paper are Drs. Fernandino Fontanilla, Suruchi Kaul, Ozlem Sahin and Howard Tessler, all of UIC.

For more information about UIC, visit www.uic.edu.

University of Illinois at Chicago

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.